Glutamate dehydrogenase 1 (GLUD1) and GLUD2, which catalyze oxidative deamination of glutamate to 2-OG, are significantly elevated in mutIDH1R132H glioma compared with WT IDH1 glioma,104,212,213,221,222 indicating the potential for increased glutamate utilization by the TCA cycle. The gene discussed is GLUD1; the disease is central nervous system cancer.